Insmed Incorporated (Nasdaq: INSM) filed a Current Report on Form 8-K reporting a Regulation FD disclosure tied to new clinical-study communications rather than a financing, acquisition, insider transaction, or share issuance. On July 16, 2026, Insmed announced that it had issued a press release with 12-month safety and efficacy data from its ongoing open-label extension study of treprostinil palmitil inhalation powder in patients with pulmonary arterial hypertension. The company described the study as an “OLE Study,” meaning patients are being followed in an open-label extension setting after prior participation in a related clinical trial or treatment period. The 8-K does not include the numerical safety or efficacy results in the body of the filing itself, but it incorporates the company’s July 16 press release as Exhibit 99.1 and a slide presentation for the same date as Exhibit 99.2. Insmed also said it would host a conference call to discuss the 12-month OLE data on July 16, 2026, at 8:00 a.m. Eastern Time, with a live webcast available through the investor relations section of its website. The filing was made under Item 7.01, Regulation FD Disclosure, which companies commonly use to broadly disseminate material or potentially material information to investors at the same time. Insmed stated that the information in Item 7.01, including the press release and presentation, is being furnished and is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, unless specifically incorporated by reference in a later filing. No securities transaction is reported in this 8-K. There are no share counts, prices, insider transaction codes, option exercises, vesting events, or changes in beneficial ownership disclosed. The significance of the filing is that Insmed is formally notifying the market of updated longer-term clinical data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension, an area relevant to the company’s development pipeline and investor assessment of the therapy’s safety, durability, and potential regulatory or commercial prospects.